other material
confidence high
sentiment positive
materiality 0.75
Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial
Cardiff Oncology, Inc.
- Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.
- ONSEMBLE: 50% ORR (2/4) in bev naïve patients on onvansertib+SoC vs 0% in control; no responses in bev exposed.
- First patient dosed in Phase 2 first-line CRDF-004 trial for RAS-mutated mCRC; topline data expected mid-2024.
- Pfizer Ignite handling clinical execution; FDA accepted ORR as endpoint for potential accelerated approval.
- FY2023 operating expenses $45.9M, net cash used $30.9M; decrease from $33.8M in FY2022.